--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-21-292225" form_type: "8-K" ticker: "XERS" cik: "0001867096" company_name: "Xeris Biopharma Holdings, Inc." filed_at: "2021-10-05T23:59:59+00:00" generated_at: "2026-06-28T23:07:48.911371+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # Xeris Biopharma closes merger with Strongbridge; appoints new board and officers ## Summary - Board expanded from 1 to 8 directors; members include prior directors from Xeris and Strongbridge. - New officers: John Shannon as President/COO, Kenneth Johnson as SVP Global Development, Beth Hecht as Chief Legal Officer, Steven Prestrelski as Chief Scientific Officer. - CEO Paul Edick gets amended employment: base salary $667,244, target bonus 60%; severance up to 24 months base upon change-in-control termination. - COO Shannon base salary $500,000 with 50% target bonus; CFO Pieper base salary $375,000 with 40% target bonus. - Assumed legacy equity plans from both Xeris (2018 Plan, ESPP, Inducement Plan) and Strongbridge (2015 Plan, Director Plan, 2017 Inducement Plan). ## SEC filing metadata - accession: 0001193125-21-292225 - form_type: 8-K - ticker: XERS - cik: 0001867096 - company_name: Xeris Biopharma Holdings, Inc. - filed_at: 2021-10-05T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 5.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/d184152d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-21-292225 - JSON: https://secwatch.observer/filing/0001193125-21-292225.json - Plain text: https://secwatch.observer/filing/0001193125-21-292225.txt ## Key facts - Executive change Dawn Halkuff was appointed as Director at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Director source text: each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change John H. Johnson was appointed as Director at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Director source text: each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change Steven Prestrelski was appointed as Chief Scientific Officer at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Chief Scientific Officer source text: the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change BJ Bormann was appointed as Director at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Director source text: each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change John Shannon was appointed as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: President and Chief Operating Officer source text: the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change Beth P. Hecht was appointed as Senior Vice President, Chief Legal Officer & Corporate Secretary at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Senior Vice President, Chief Legal Officer & Corporate Secretary source text: the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change John Schmid was appointed as Director at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Director source text: each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change Jeffrey W. Sherman was appointed as Director at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Director source text: each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change Kenneth Johnson was appointed as Senior Vice President, Global Development and Medical Affairs at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Senior Vice President, Global Development and Medical Affairs source text: the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change Marla S. Persky was appointed as Director at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Director source text: each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm - Executive change Garheng Kong was appointed as Director at Xeris Biopharma Holdings, Inc.. - Action: appointed - Role: Director source text: each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000119312521292225/0001193125-21-292225-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.